Stem cell therapy for ALS

Hope and reality a discussion paper from the executive of the European ALS consortium

Vincenzo Silani, Nigel Leigh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background All are agreed that there is pressing need for an effective treatment for Amyotrophic Lateral Sclerosis (ALS; MND). Such treatment may derive from a combination of therapeutic strategies aimed at different aspects of the disorder, and might include drugs directed at the initial, intermediate or terminal cascade of events leading to cell death, as well as the use of stem cells to replace dead motor neurons, or to protect those that remain. The attraction of cell implantation or transplantation is that it might help to overcome the inability of the CNS to replace lost neurons. It is also clear that neural implantation will yield little benefit if the donor cells fail to integrate functionally into the recipient CNS circuitry. In this respect, ALS poses an especially difficult problem. The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS. The potential impact of these new approaches to neurodegenerative diseases has been emphasised by the many experiments using human foetal cell grafts in patients affected by Parkinson's and Huntington's disease. Clinical benefits in Parkinson's disease seem to be associated with integration of the donor cells into the recipient brain. Despite promising results, however, significant constraints have hampered the use of foetal cells for neural implantation and transplantation. Besides ethical concerns, the viability, purity, and final destiny of the foetal tissue have not been completely defined. Foetal cells are, in addition, post-mitotic and cannot be expanded or stored for long periods, necessitating close synchronisation of tissue donation and neurosurgery.

Original languageEnglish
Pages (from-to)8-10
Number of pages3
JournalAmyotrophic Lateral Sclerosis
Volume4
Issue number1
DOIs
Publication statusPublished - 2003

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Parkinson Disease
Transplantation
Tissue Donors
Stem Cell Research
Tissue and Organ Procurement
Huntington Disease
Amyotrophic Lateral Sclerosis
Neurosurgery
Motor Neurons
Neurodegenerative Diseases
Fetus
Cell Death
Therapeutics
Transplants
Neurons
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Stem cell therapy for ALS : Hope and reality a discussion paper from the executive of the European ALS consortium. / Silani, Vincenzo; Leigh, Nigel.

In: Amyotrophic Lateral Sclerosis, Vol. 4, No. 1, 2003, p. 8-10.

Research output: Contribution to journalArticle

@article{6396d9c622d74d899b8e288ea053b873,
title = "Stem cell therapy for ALS: Hope and reality a discussion paper from the executive of the European ALS consortium",
abstract = "Background All are agreed that there is pressing need for an effective treatment for Amyotrophic Lateral Sclerosis (ALS; MND). Such treatment may derive from a combination of therapeutic strategies aimed at different aspects of the disorder, and might include drugs directed at the initial, intermediate or terminal cascade of events leading to cell death, as well as the use of stem cells to replace dead motor neurons, or to protect those that remain. The attraction of cell implantation or transplantation is that it might help to overcome the inability of the CNS to replace lost neurons. It is also clear that neural implantation will yield little benefit if the donor cells fail to integrate functionally into the recipient CNS circuitry. In this respect, ALS poses an especially difficult problem. The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS. The potential impact of these new approaches to neurodegenerative diseases has been emphasised by the many experiments using human foetal cell grafts in patients affected by Parkinson's and Huntington's disease. Clinical benefits in Parkinson's disease seem to be associated with integration of the donor cells into the recipient brain. Despite promising results, however, significant constraints have hampered the use of foetal cells for neural implantation and transplantation. Besides ethical concerns, the viability, purity, and final destiny of the foetal tissue have not been completely defined. Foetal cells are, in addition, post-mitotic and cannot be expanded or stored for long periods, necessitating close synchronisation of tissue donation and neurosurgery.",
author = "Vincenzo Silani and Nigel Leigh",
year = "2003",
doi = "10.1080/1466082031006652",
language = "English",
volume = "4",
pages = "8--10",
journal = "Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders",
issn = "1466-0822",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Stem cell therapy for ALS

T2 - Hope and reality a discussion paper from the executive of the European ALS consortium

AU - Silani, Vincenzo

AU - Leigh, Nigel

PY - 2003

Y1 - 2003

N2 - Background All are agreed that there is pressing need for an effective treatment for Amyotrophic Lateral Sclerosis (ALS; MND). Such treatment may derive from a combination of therapeutic strategies aimed at different aspects of the disorder, and might include drugs directed at the initial, intermediate or terminal cascade of events leading to cell death, as well as the use of stem cells to replace dead motor neurons, or to protect those that remain. The attraction of cell implantation or transplantation is that it might help to overcome the inability of the CNS to replace lost neurons. It is also clear that neural implantation will yield little benefit if the donor cells fail to integrate functionally into the recipient CNS circuitry. In this respect, ALS poses an especially difficult problem. The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS. The potential impact of these new approaches to neurodegenerative diseases has been emphasised by the many experiments using human foetal cell grafts in patients affected by Parkinson's and Huntington's disease. Clinical benefits in Parkinson's disease seem to be associated with integration of the donor cells into the recipient brain. Despite promising results, however, significant constraints have hampered the use of foetal cells for neural implantation and transplantation. Besides ethical concerns, the viability, purity, and final destiny of the foetal tissue have not been completely defined. Foetal cells are, in addition, post-mitotic and cannot be expanded or stored for long periods, necessitating close synchronisation of tissue donation and neurosurgery.

AB - Background All are agreed that there is pressing need for an effective treatment for Amyotrophic Lateral Sclerosis (ALS; MND). Such treatment may derive from a combination of therapeutic strategies aimed at different aspects of the disorder, and might include drugs directed at the initial, intermediate or terminal cascade of events leading to cell death, as well as the use of stem cells to replace dead motor neurons, or to protect those that remain. The attraction of cell implantation or transplantation is that it might help to overcome the inability of the CNS to replace lost neurons. It is also clear that neural implantation will yield little benefit if the donor cells fail to integrate functionally into the recipient CNS circuitry. In this respect, ALS poses an especially difficult problem. The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS. The potential impact of these new approaches to neurodegenerative diseases has been emphasised by the many experiments using human foetal cell grafts in patients affected by Parkinson's and Huntington's disease. Clinical benefits in Parkinson's disease seem to be associated with integration of the donor cells into the recipient brain. Despite promising results, however, significant constraints have hampered the use of foetal cells for neural implantation and transplantation. Besides ethical concerns, the viability, purity, and final destiny of the foetal tissue have not been completely defined. Foetal cells are, in addition, post-mitotic and cannot be expanded or stored for long periods, necessitating close synchronisation of tissue donation and neurosurgery.

UR - http://www.scopus.com/inward/record.url?scp=80051572629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051572629&partnerID=8YFLogxK

U2 - 10.1080/1466082031006652

DO - 10.1080/1466082031006652

M3 - Article

VL - 4

SP - 8

EP - 10

JO - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

JF - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

SN - 1466-0822

IS - 1

ER -